Microenvironment and brain tumor stem cell maintenance: Impact of the niche

Anti-Cancer Agents in Medicinal Chemistry

Volumn 14, Issue 8, 2014, Pages 1065-1074

  Herold Mende, Christel ^a   Mock, Andreas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Brain tumor stem cells; Glioblastoma; Hypoxia; Maintenance; Niche

Indexed keywords

CD133 ANTIGEN; NITRIC OXIDE; TUMOR MARKER;

ACIDOSIS; ARTICLE; ASTROCYTE; BRAIN TUMOR; CANCER STEM CELL; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; HYPOXIC NICHE; INVASIVE NICHE; MACROPHAGE; MICROGLIA; NOTCH PATHWAY; PERIVASCULAR NICHE; SIGNAL TRANSDUCTION; SONIC HEDGEHOG PATHWAY; STEM CELL NICHE; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; WNT SIGNALING PATHWAY; ANIMAL; CHEMISTRY; PATHOLOGY; PHENOTYPE;

ANIMALS; BRAIN NEOPLASMS; HUMANS; NEOPLASTIC STEM CELLS; PHENOTYPE; SIGNAL TRANSDUCTION; STEM CELL NICHE; TUMOR MICROENVIRONMENT;

EID: 84907179967     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520614666140825103636     Document Type: Article

References (136)

1. Lapidot, T.; Sirard, C.; Vormoor, J.; Murdoch, B.; Hoang, T.; Caceres-Cortes, J.; Minden, M.; Paterson, B.; Caligiuri, M.A.; Dick, J.E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 1994, 367(6464), 645-648.
2. Bonnet, D.; Dick, J.E. Human acute myeloid leukemia is organizedas a hierarchy that originates from a primitive hematopoietic cell. Nat. Med., 1997, 3(7), 730-737.
3. Lander, A.D.; Kimble, J.; Clevers, H.; Fuchs, E.; Montarras, D.; Buckingham, M.; Calof, A.L.; Trumpp, A.; Oskarsson, T. What does the concept of the stem cell niche really mean today? BMC Biol., 2012, 10, 19.
4. Eramo, A.; Lotti, F.; Sette, G.; Pilozzi, E.; Biffoni, M.; Di Virgilio, A.; Conticello, C.; Ruco, L.; Peschle, C.; De Maria, R. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ., 2008, 15(3), 504-514.
5. Al-Hajj, M.; Wicha, M.S.; Benito-Hernandez, A.; Morrison, S.J.; Clarke, M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA, 2003, 100(7), 3983-3988.
6. Ricci-Vitiani, L.; Lombardi, D.G.; Pilozzi, E.; Biffoni, M.; Todaro, M.; Peschle, C.; De Maria, R. Identification and expansion of human colon-cancer-initiating cells. Nature, 2007, 445(7123), 111-115.
7. Prince, M.E.; Sivanandan, R.; Kaczorowski, A.; Wolf, G.T.; Kaplan, M.J.; Dalerba, P.; Weissman, I.L.; Clarke, M.F.; Ailles, L.E. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl. Acad. Sci. USA, 2007, 104(3), 973-978.
8. Singh, S.K.; Clarke, I.D.; Terasaki, M.; Bonn, V.E.; Hawkins, C.; Squire, J.; Dirks, P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res., 2003, 63 (18), 5821-5828.
9. Singh, S.K.; Hawkins, C.; Clarke, I.D.; Squire, J.A.; Bayani, J.; Hide, T.; Henkelman, R.M.; Cusimano, M.D.; Dirks, P.B. Identification of human brain tumour initiating cells. Nature, 2004, 432(7015), 396-401.
10. Uchida, N.; Buck, D.W.; He, D.; Reitsma, M.J.; Masek, M.; Phan, T.V.; Tsukamoto, A.S.; Gage, F.H.; Weissman, I.L. Direct isolation of human central nervous system stem cells. Proc. Natl. Acad. Sci. USA, 2000, 97(26), 14720-14725.
11. Huszthy, P.C.; Daphu, I.; Niclou, S.P.; Stieber, D.; Nigro, J.M.; Sakariassen, P.O.; Miletic, H.; Thorsen, F.; Bjerkvig, R. In vivo models of primary brain tumors: Pitfalls and perspectives. Neuro. Oncol., 2012, 14(8), 979-993.
12. Campos, B.; Wan, F.; Farhadi, M.; Ernst, A.; Zeppernick, F.; Tagscherer, K.E.; Ahmadi, R.; Lohr, J.; Dictus, C.; Gdynia, G.; Combs, S.E.; Goidts, V.; Helmke, B.M.; Eckstein, V.; Roth, W.; Beckhove, P.; Lichter, P.; Unterberg, A.; Radlwimmer, B.; Herold-Mende, C. Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin. Cancer Res., 2010, 16(10), 2715-2728.
13. Hemmati, H.D.; Nakano, I.; Lazareff, J.A.; Masterman-Smith, M.; Geschwind, D.H.; Bronner-Fraser, M.; Kornblum, H.I. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl. Acad. Sci. USA, 2003, 100(25), 15178-15183.
14. Yuan, X.; Curtin, J.; Xiong, Y.; Liu, G.; Waschsmann-Hogiu, S.; Farkas, D.L.; Black, K.L.; Yu, J.S. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene, 2004, 23(58), 9392-9400.
15. Beier, D.; Wischhusen, J.; Dietmaier, W.; Hau, P.; Proescholdt, M.; Brawanski, A.; Bogdahn, U.; Beier, C.P. CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors. Brain Pathol., 2008, 18(3), 370-377.
16. Zeppernick, F.; Ahmadi, R.; Campos, B.; Dictus, C.; Helmke, B.M.; Becker, N.; Lichter, P.; Unterberg, A.; Radlwimmer, B.; Herold-Mende, C.C. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin. Cancer Res., 2008, 14(1), 123-129.
17. Rebetz, J.; Tian, D.; Persson, A.; Widegren, B.; Salford, L.G.; Englund, E.; Gisselsson, D.; Fan, X. Glial progenitor-like phenotype in low-grade glioma and enhanced CD133-expression and neuronal lineage differentiation potential in high-grade glioma. PLoS One, 2008, 3(4), e1936.
18. Pallini, R.; Ricci-Vitiani, L.; Banna, G.L.; Signore, M.; Lombardi, D.; Todaro, M.; Stassi, G.; Martini, M.; Maira, G.; Larocca, L.M.; De Maria, R. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin. Cancer Res., 2008, 14(24), 8205-8212.
19. Thon, N.; Damianoff, K.; Hegermann, J.; Grau, S.; Krebs, B.; Schnell, O.; Tonn, J.C.; Goldbrunner, R. Presence of pluripotent CD133+ cells correlates with malignancy of gliomas. Mol. Cell Neurosci., 2010, 43(1), 51-59.
20. Yan, X.; Ma, L.; Yi, D.; Yoon, J.G.; Diercks, A.; Foltz, G.; Price, N.D.; Hood, L.E.; Tian, Q. A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. Proc. Natl. Acad. Sci. USA, 2011, 108(4), 1591-1596.
21. Griguer, C.E.; Oliva, C.R.; Gobin, E.; Marcorelles, P.; Benos, D.J.; Lancaster, J.R.; Jr.; Gillespie, G.Y. CD133 is a marker of bioenergetic stress in human glioma. PLoS One, 2008, 3(11), e3655.
22. Campos, B.; Herold-Mende, C.C. Insight into the complexregulation of CD133 in glioma. Int. J. Cancer, 2011, 128(3), 501-510.
23. Campos, B.; Zeng, L.; Daotrong, P.H.; Eckstein, V.; Unterberg, A.; Mairbaurl, H.; Herold-Mende, C. Expression and regulation of AC133 and CD133 in glioblastoma. Glia, 2011, 59(12), 1974-1986.
24. Beier, D.; Hau, P.; Proescholdt, M.; Lohmeier, A.; Wischhusen, J.; Oefner, P.J.; Aigner, L.; Brawanski, A.; Bogdahn, U.; Beier, C.P. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res., 2007, 67(9), 4010-4015.
25. Wang, J.; Sakariassen, P.O.; Tsinkalovsky, O.; Immervoll, H.; Boe, S.O.; Svendsen, A.; Prestegarden, L.; Rosland, G.; Thorsen, F.; Stuhr, L.; Molven, A.; Bjerkvig, R.; Enger, P.O. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int. J. Cancer, 2008, 122(4), 761-768.
26. Chen, R.; Nishimura, M.C.; Bumbaca, S.M.; Kharbanda, S.; Forrest, W.F.; Kasman, I.M.; Greve, J.M.; Soriano, R.H.; Gilmour, L.L.; Rivers, C.S.; Modrusan, Z.; Nacu, S.; Guerrero, S.; Edgar, K.A.; Wallin, J.J.; Lamszus, K.; Westphal, M.; Heim, S.; James, C.D.; VandenBerg, S.R.; Costello, J.F.; Moorefield, S.; Cowdrey, C.J.; Prados, M.; Phillips, H.S. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell, 2010, 17(4), 362-375.
27. Gunther, H.S.; Schmidt, N.O.; Phillips, H.S.; Kemming, D.; Kharbanda, S.; Soriano, R.; Modrusan, Z.; Meissner, H.; Westphal, M.; Lamszus, K. Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene, 2008, 27(20), 2897-2909.
28. Lathia, J.D.; Gallagher, J.; Heddleston, J.M.; Wang, J.; Eyler, C.E.; Macswords, J.; Wu, Q.; Vasanji, A.; McLendon, R.E.; Hjelmeland, A.B.; Rich, J.N. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell, 2010, 6(5), 421-432.
29. Ogden, A.T.; Waziri, A.E.; Lochhead, R.A.; Fusco, D.; Lopez, K.; Ellis, J.A.; Kang, J.; Assanah, M.; McKhann, G. M.; Sisti, M.B.; McCormick, P.C.; Canoll, P.; Bruce, J.N. Identification of A2B5+CD133-tumor-initiating cells in adult human gliomas. Neurosurgery, 2008, 62(2), 505-514.
30. Son, M.J.; Woolard, K.; Nam, D.H.; Lee, J.; Fine, H.A. SSEA-1 isan enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell, 2009, 4 (5), 440-452.
31. Nakata, S.; Campos, B.; Bageritz, J.; Lorenzo Bermejo, J.; Becker, N.; Engel, F.; Acker, T.; Momma, S.; Herold-Mende, C.; Lichter, P.; Radlwimmer, B.; Goidts, V. LGR5 is a marker of poor prognosis in glioblastoma and is required for survival of brain cancer stem-like cells. Brain Pathol., 2013, 23(1), 60-72.
32. Wan, F.; Herold-Mende, C.; Campos, B.; Centner, F.S.; Dictus, C.; Becker, N.; Devens, F.; Mogler, C.; Felsberg, J.; Grabe, N.; Reifenberger, G.; Lichter, P.; Unterberg, A.; Bermejo, J.L.; Ahmadi, R. Association of stem cell-related markers and survival in astrocytic gliomas. Biomarkers, 2011, 16(2), 136-143.
33. Chen, J.; Li, Y.; Yu, T.S.; McKay, R.M.; Burns, D.K.; Kernie, S.G.; Parada, L.F. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature, 2012, 488(7412), 522-526.
34. Driessens, G.; Beck, B.; Caauwe, A.; Simons, B.D.; Blanpain, C. Defining the mode of tumour growth by clonal analysis. Nature, 2012, 488(7412), 527-530.
35. Schepers, A.G.; Snippert, H.J.; Stange, D.E.; Van Den Born, M.; Van Es, J.H.; Van De Wetering, M.; Clevers, H. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science, 2012, 337(6095), 730-735.
36. Gilbertson, R.J.; Graham, T.A. Cancer: Resolving the stem-celldebate. Nature, 2012, 488(7412), 462-463.
37. Solecki, D.J.; Liu, X.L.; Tomoda, T.; Fang, Y.; Hatten, M.E. Activated Notch2 signaling inhibits differentiation of cerebellar granule neuron precursors by maintaining proliferation. Neuron, 2001, 31(4), 557-568.
38. Androutsellis-Theotokis, A.; Leker, R.R.; Soldner, F.; Hoeppner, D.J.; Ravin, R.; Poser, S.W.; Rueger, M.A.; Bae, S.K.; Kittappa, R.; McKay, R.D. Notch signalling regulates stem cell numbers in vitro and in vivo. Nature, 2006, 442(7104), 823-826.
39. Zhang, X.P.; Zheng, G.; Zou, L.; Liu, H.L.; Hou, L.H.; Zhou, P.; Yin, D.D.; Zheng, Q.J.; Liang, L.; Zhang, S.Z.; Feng, L.; Yao, L.B.; Yang, A.G.; Han, H.; Chen, J.Y. Notch activation promotes cell proliferation and the formation of neural stem cell-like colonies in human glioma cells. Mol. Cell Biochem., 2008, 307(1-2), 101-108.
40. Shih, A.H.; Holland, E.C. Notch signaling enhances nestinexpression in gliomas. Neoplasia, 2006, 8(12), 1072-82.
41. Wang, J.; Wakeman, T.P.; Lathia, J.D.; Hjelmeland, A.B.; Wang, X.F.; White, R.R.; Rich, J.N.; Sullenger, B.A. Notch promotes radioresistance of glioma stem cells. Stem Cells, 2010, 28(1), 17-28.
42. Wechsler-Reya, R.J.; Scott, M.P. Control of neuronal precursorproliferation in the cerebellum by Sonic Hedgehog. Neuron, 1999, 22(1), 103-114.
43. Bar, E.E.; Chaudhry, A.; Lin, A.; Fan, X.; Schreck, K.; Matsui, W.; Piccirillo, S.; Vescovi, A.L.; DiMeco, F.; Olivi, A.; Eberhart, C.G. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells, 2007, 25(10), 2524-2533.
44. Takezaki, T.; Hide, T.; Takanaga, H.; Nakamura, H.; Kuratsu, J.; Kondo, T. Essential role of the Hedgehog signaling pathway in human glioma-initiating cells. Cancer Sci., 2011, 102(7), 1306-1312.
45. Clement, V.; Sanchez, P.; De Tribolet, N.; Radovanovic, I.; Ruiz i Altaba, A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr. Biol., 2007, 17(2), 165-172.
46. Zheng, H.; Ying, H.; Wiedemeyer, R.; Yan, H.; Quayle, S.N.; Ivanova, E.V.; Paik, J.H.; Zhang, H.; Xiao, Y.; Perry, S.R.; Hu, J.; Vinjamoori, A.; Gan, B.; Sahin, E.; Chheda, M.G.; Brennan, C.; Wang, Y.A.; Hahn, W.C.; Chin, L.; DePinho, R.A. PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell, 2010, 17(5), 497-509.
47. Augustin, I.; Goidts, V.; Bongers, A.; Kerr, G.; Vollert, G.; Radlwimmer, B.; Hartmann, C.; Herold-Mende, C.; Reifenberger, G.; Von Deimling, A.; Boutros, M. The Wnt secretion protein Evi/Gpr177 promotes glioma tumourigenesis. EMBO Mol. Med., 2012, 4(1), 38-51.
48. Kim, J.H.; Park, J.A.; Lee, S.W.; Kim, W.J.; Yu, Y.S.; Kim, K.W. Blood-neural barrier: Intercellular communication at glio-vascular interface. J. Biochem. Mol. Biol., 2006, 39(4), 339-345.
49. Seidel, S.; Garvalov, B.K.; Wirta, V.; Von Stechow, L.; Schanzer, A.; Meletis, K.; Wolter, M.; Sommerlad, D.; Henze, A.T.; Nister, M.; Reifenberger, G.; Lundeberg, J.; Frisen, J.; Acker, T.A. Hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain, 2010, 133(Pt 4), 983-995.
50. Hjelmeland, A.B.; Wu, Q.; Heddleston, J.M.; Choudhary, G.S.; MacSwords, J.; Lathia, J.D.; McLendon, R.; Lindner, D.; Sloan, A.; Rich, J.N. Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ., 2011, 18(5), 829-840.
51. Moore, K.A.; Lemischka, I.R. Stem cells and their niches. Science,2006, 311(5769), 1880-1885.
52. Scheres, B. Stem-cell niches: Nursery rhymes across kingdoms. Nat. Rev. Mol. Cell Biol., 2007, 8(5), 345-354.
53. Shen, Q.; Goderie, S.K.; Jin, L.; Karanth, N.; Sun, Y.; Abramova, N.; Vincent, P.; Pumiglia, K.; Temple, S. Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. Science, 2004, 304(5675), 1338-1340.
54. Calabrese, C.; Poppleton, H.; Kocak, M.; Hogg, T.L.; Fuller, C.; Hamner, B.; Oh, E.Y.; Gaber, M.W.; Finklestein, D.; Allen, M.; Frank, A.; Bayazitov, I.T.; Zakharenko, S.S.; Gajjar, A.; Davidoff, A.; Gilbertson, R.J. A perivascular niche for brain tumor stem cells. Cancer Cell, 2007, 11(1), 69-82.
55. Wen, P.Y.; Kesari, S. Malignant gliomas in adults. N. Engl. J.Med., 2008, 359 (5), 492-507.
56. Bulnes, S., Bengoetxea H.; Ortuzar, N.; Argandoña, E.G.; Lafuente, J.V. Endogenous experimental glioma model, links between glioma stem cells and angiogenesis. In: Glioma - Exploring Its Biology and Practical Relevance, Anirban, G., Ed. InTech: 2011.
57. Dieterich, L.C.; Mellberg, S.; Langenkamp, E.; Zhang, L.; Zieba, A.; Salomaki, H.; Teichert, M.; Huang, H.; Edqvist, P.H.; Kraus, T.; Augustin, H.G.; Olofsson, T.; Larsson, E.; Soderberg, O.; Molema, G.; Ponten, F.; Georgii-Hemming, P.; Alafuzoff, I.; Dimberg, A. Transcriptional profiling of human glioblastoma vessels indicates a key role of VEGF-A and TGF-beta2 in vascular abnormalization. J. Pathol., 2012, 228(3), 378-390.
58. Bian, X.W.; Jiang, X.F.; Chen, J.H.; Bai, J.S.; Dai, C.; Wang, Q.L.; Lu, J.Y.; Zhao, W.; Xin, R.; Liu, M.Y.; Shi, J.Q.; Wang, J.M. Increased angiogenic capabilities of endothelial cells frommicrovessels of malignant human gliomas. Int. Immunopharmacol., 2006, 6(1), 90-99.
59. Herold-Mende, C.; Mueller, M.M.; Bonsanto, M.M.; Schmitt, H.P.; Kunze, S.; Steiner, H.H. Clinical impact and functional aspects of tenascin-C expression during glioma progression. Int. J. Cancer, 2002, 98(3), 362-369.
60. Alves, T.R.; Da Fonseca, A.C.; Nunes, S.S.; da Silva, A.O.; Dubois, L.G.; Faria, J.; Kahn, S.A.; Viana, N.B.; Marcondes, J.; Legrand, C.; Moura-Neto, V.; Morandi, V. Tenascin-C in the extracellular matrix promotes the selection of highly proliferative and tubulogenesis-defective endothelial cells. Exp. Cell Res., 2011, 317(15), 2073-2085.
61. Lohr, J.; Ratliff, T.; Huppertz, A.; Ge, Y.; Dictus, C.; Ahmadi, R.; Grau, S.; Hiraoka, N.; Eckstein, V.; Ecker, R.; Korff, T.; Von Deimling, A.; Unterberg, A.; Beckhove, P.; Herold-Mende, C.C. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived transforming growth factor-betas. Clin. Cancer Res., 2011, 17(13), 4296-4308.
62. Von Tell, D.; Armulik, A.; Betsholtz, C. Pericytes and vascularstability. Exp. Cell Res., 2006, 312 (5), 623-9.
63. Sims, D.E.; Diversity within pericytes. Clin. Exp. Pharmacol.Physiol., 2000, 27(10), 842-846.
64. Benninghoff, A.; Drenckhahn, D. Anatomie. 16th ed.; ElsevierGmbH: München, 2004.
65. Hellstrom, M.; Kalen, M.; Lindahl, P.; Abramsson, A.; Betsholtz, C. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development, 1999, 126(14), 3047-3055.
66. Guo, P.; Hu, B.; Gu, W.; Xu, L.; Wang, D.; Huang, H.J.; Cavenee, W.K.; Cheng, S.Y. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am. J. Pathol., 2003, 162(4), 1083-1093.
67. Hashizume, H.; Baluk, P.; Morikawa, S.; McLean, J.W.; Thurston, G.; Roberge, S.; Jain, R.K.; McDonald, D.M. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol., 2000, 156(4), 1363-1380.
68. Hammes, H.P. Pericytes and the pathogenesis of diabeticretinopathy. Horm. Metab. Res., 2005, 37(Suppl 1), 39-43.
69. Stallcup, W.B.; Huang, F.J. A role for the NG2 proteoglycan inglioma progression. Cell Adh. Migr., 2008, 2(3), 192-201.
70. Kalluri, R.; Zeisberg, M. Fibroblasts in cancer. Nat. Rev. Cancer,2006, 6(5), 392-401.
71. Cirri, P.; Chiarugi, P. Cancer associated fibroblasts: The dark sideof the coin. Am. J. Cancer Res., 2011, 1(4), 482-497.
72. Sameshima, T.; Nabeshima, K.; Toole, B.P.; Yokogami, K.; Okada, Y.; Goya, T.; Koono, M.; Wakisaka, S. Glioma cell extracellular matrix metalloproteinase inducer (EMMPRIN) (CD147) stimulates production of membrane-type matrix metalloproteinases and activated gelatinase A in co-cultures with brain-derived fibroblasts. Cancer Lett., 2000, 157(2), 177-184.
73. Yang, C.; Iyer, R.R.; Yu, A.C.; Yong, R.L.; Park, D.M.; Weil, R.J.; Ikejiri, B.; Brady, R.O.; Lonser, R.R.; Zhuang, Z. Beta-Catenin signaling initiates the activation of astrocytes and its dysregulation contributes to the pathogenesis of astrocytomas. Proc. Natl. Acad. Sci. USA, 2012, 109(18), 6963-6968.
74. Charles, N.A.; Holland, E.C.; Gilbertson, R.; Glass, R.; Kettenmann, H. The brain tumor microenvironment. Glia, 2012, 60(3), 502-14.
75. Le, D.M.; Besson, A.; Fogg, D.K.; Choi, K.S.; Waisman, D.M.; Goodyer, C.G.; Rewcastle, B.; Yong, V.W. Exploitation of astrocytes by glioma cells to facilitate invasiveness: A mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade. J. Neurosci., 2003, 23(10), 4034-4043.
76. Hoelzinger, D.B.; Demuth, T.; Berens, M.E. Autocrine factors thatsustain glioma invasion and paracrine biology in the brain microenvironment. J. Natl. Cancer Inst., 2007, 99(21), 1583-1593.
77. Carrillo-de Sauvage, M.A.; Gomez, A.; Ros, C.M.; Ros-Bernal, F.; Martin, E.D.; Perez-Valles, A.; Gallego-Sanchez, J.M.; Fernandez-Villalba, E.; Barcia, C.S.R.; Barcia, C.JR.; Herrero, M.T. CCL2-expressing astrocytes mediate the extravasation of T lymphocytes in the brain. Evidence from patients with glioma and experimental models in vivo. PLoS One, 2012, 7(2), e30762.
78. Becher, O.J.; Hambardzumyan, D.; Fomchenko, E.I.; Momota, H.; Mainwaring, L.; Bleau, A.M.; Katz, A.M.; Edgar, M.; Kenney, A.M.; Cordon-Cardo, C.; Blasberg, R.G.; Holland, E.C. Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas. Cancer Res., 2008, 68(7), 2241-2249.
79. Parsons, D.W.; Jones, S.; Zhang, X.; Lin, J.C.; Leary, R.J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I.M.; Gallia, G.L.; Olivi, A.; McLendon, R.; Rasheed, B.A.; Keir, S.; Nikolskaya, T.; Nikolsky, Y.; Busam, D.A.; Tekleab, H.; Diaz, L.A., Jr.; Hartigan, J.; Smith, D.R.; Strausberg, R.L.; Marie, S.K.; Shinjo, S.M.; Yan, H.; Riggins, G.J.; Bigner, D.D.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V.E.; Kinzler, K.W. An integrated genomic analysis of human glioblastoma multiforme. Science, 2008, 321(5897), 1807-1812.
80. Capper, D.; Zentgraf, H.; Balss, J.; Hartmann, C.; Von Deimling, A. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol., 2009, 118(5), 599-601.
81. Ginhoux, F.; Greter, M.; Leboeuf, M.; Nandi, S.; See, P.; Gokhan, S.; Mehler, M.F.; Conway, S.J.; Ng, L.G.; Stanley, E.R.; Samokhvalov, I.M.; Merad, M. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science, 2010, 330(6005), 841-845.
82. Mildner, A.; Schmidt, H.; Nitsche, M.; Merkler, D.; Hanisch, U.K.; Mack, M.; Heikenwalder, M.; Bruck, W.; Priller, J.; Prinz, M. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat. Neurosci., 2007, 10(12), 1544-1553.
83. Clausen, B.H.; Lambertsen, K.L.; Babcock, A.A.; Holm, T.H.; Dagnaes-Hansen, F.; Finsen, B. Interleukin-1beta and tumor necrosis factor-alpha are expressed by different subsets of microglia and macrophages after ischemic stroke in mice. J. Neuroinflam., 2008, 5, 1-46.
84. Flugel, A.; Bradl, M.; Kreutzberg, G.W.; Graeber, M.B. Transformation of donor-derived bone marrow precursors into host microglia during autoimmune CNS inflammation and during the retrograde response to axotomy. J. Neurosci. Res., 2001, 66(1), 74-82.
85. Simard, A.R.; Soulet, D.; Gowing, G.; Julien, J.P.; Rivest, S. Bonemarrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron, 2006, 49(4), 489-502.
86. AlShakweer, W.; Alwelaie, Y.; Mankung, A.M.; Graeber, M.B. Bone marrow-derived microglia in pilocytic astrocytoma. Front. Biosci., 2011, 3, 371-379.
87. Gabrusiewicz, K.; Ellert-Miklaszewska, A.; Lipko, M.; Sielska, M.; Frankowska, M.; Kaminska, B. Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas. PLoS One, 2011, 6(8), e23902.
88. Giometto, B.; Bozza, F.; Faresin, F.; Alessio, L.; Mingrino, S.; Tavolato, B. Immune infiltrates and cytokines in gliomas. Acta Neurochir., 1996, 138(1), 50-56.
89. Badie, B.; Schartner, J. Role of microglia in glioma biology. Microsc. Res. Tech., 2001, 54 (2), 106-113.
90. Aloisi, F. Immune function of microglia. Glia, 2001, 36(2), 165-179.
91. Li, W.; Graeber, M.B. The molecular profile of microglia under theinfluence of glioma. Neuro. Oncol., 2012, 14(8), 958-978.
92. Wu, A.; Wei, J.; Kong, L.Y.; Wang, Y.; Priebe, W.; Qiao, W.; Sawaya, R.; Heimberger, A.B. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro. Oncol., 2010, 12(11), 1113-1125.
93. Komohara, Y.; Ohnishi, K.; Kuratsu, J.; Takeya, M. Possibleinvolvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J. Pathol., 2008, 216(1), 15-24.
94. Kees, T.; Lohr, J.; Noack, J.; Mora, R.; Gdynia, G.; Todt, G.; Ernst, A.; Radlwimmer, B.; Falk, C.S.; Herold-Mende, C.; Regnier-Vigouroux, A. Microglia isolated from patients with glioma gain antitumor activities on poly (I:C) stimulation. Neuro. Oncol., 2012, 14(1), 64-78.
95. Black, K.L.; Chen, K.; Becker, D.P.; Merrill, J.E. Inflammatoryleukocytes associated with increased immunosuppression by glioblastoma. J. Neurosurg., 1992, 77(1), 120-126.
96. Schreiber, R.D.; Old, L.J.; Smyth, M.J. Cancer immunoediting:Integrating immunity's roles in cancer suppression and promotion. Science, 2011, 331 (6024), 1565-1570.
97. Penuelas, S.; Anido, J.; Prieto-Sanchez, R.M.; Folch, G.; Barba, I.; Cuartas, I.; Garcia-Dorado, D.; Poca, M.A.; Sahuquillo, J.; Baselga, J.; Seoane, J. TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell, 2009, 15(4), 315-327.
98. Heimberger, A.B.; Abou-Ghazal, M.; Reina-Ortiz, C.; Yang, D.S.; Sun, W.; Qiao, W.; Hiraoka, N.; Fuller, G.N. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin. Cancer Res., 2008, 14(16), 5166-5172.
99. Jacobs, J.F.; Idema, A.J.; Bol, K.F.; Grotenhuis, J.A.; De Vries, I.J.; Wesseling, P.; Adema, G.J. Prognostic significance and mechanism of Treg infiltration in human brain tumors. J. Neuroimmunol., 2010, 225(1-2), 195-199.
100. Sakaguchi, S. Naturally arising Foxp3-expressing CD25+CD4+regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol., 2005, 6(4), 345-352.
101. Wei, J.; Barr, J.; Kong, L.Y.; Wang, Y.; Wu, A.; Sharma, A.K.; Gumin, J.; Henry, V.; Colman, H.; Sawaya, R.; Lang, F.F.; Heimberger, A.B. Glioma-associated cancer-initiating cells induce immunosuppression. Clin. Cancer Res., 2010, 16(2), 461-473.
102. Zheng, P.P.; Hop, W.C.; Luider, T.M.; Sillevis Smitt, P.A.; Kros, J.M. Increased levels of circulating endothelial progenitor cells and circulating endothelial nitric oxide synthase in patients with gliomas. Ann. Neurol., 2007, 62(1), 40-48.
103. Charles, N.; Ozawa, T.; Squatrito, M.; Bleau, A.M.; Brennan, C.W.; Hambardzumyan, D.; Holland, E.C. Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell, 2010, 6(2), 141-152.
104. Eyler, C.E.; Wu, Q.; Yan, K.; MacSwords, J.M.; Chandler-Militello, D.; Misuraca, K.L.; Lathia, J.D.; Forrester, M. T.; Lee, J.; Stamler, J.S.; Goldman, S.A.; Bredel, M.; McLendon, R.E.; Sloan, A.E.; Hjelmeland, A.B.; Rich, J.N. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell, 2011, 146(1), 53-66.
105. Butler, J.M.; Nolan, D.J.; Vertes, E.L.; Varnum-Finney, B.; Kobayashi, H.; Hooper, A.T.; Seandel, M.; Shido, K.; White, I.A.; Kobayashi, M.; Witte, L.; May, C.; Shawber, C.; Kimura, Y.; Kitajewski, J.; Rosenwaks, Z.; Bernstein, I.D.; Rafii, S. Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells. Cell Stem Cell, 2010, 6(3), 251-264.
106. Hovinga, K.E.; Shimizu, F.; Wang, R.; Panagiotakos, G.; Van DerHeijden, M.; Moayedpardazi, H.; Correia, A.S.; Soulet, D.; Major, T.; Menon, J.; Tabar, V. Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells, 2010, 28(6), 1019-1029.
107. Fan, X.; Matsui, W.; Khaki, L.; Stearns, D.; Chun, J.; Li, Y.M.; Eberhart, C.G. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res., 2006, 66(15), 7445-7452.
108. Fan, X.; Khaki, L.; Zhu, T.S.; Soules, M.E.; Talsma, C.E.; Gul, N.; Koh, C.; Zhang, J.; Li, Y.M.; Maciaczyk, J.; Nikkhah, G.; Dimeco, F.; Piccirillo, S.; Vescovi, A.L.; Eberhart, C.G. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells, 2010, 28(1), 5-16.
109. Bao, S.; Wu, Q.; Sathornsumetee, S.; Hao, Y.; Li, Z.; Hjelmeland, A.B.; Shi, Q.; McLendon, R.E.; Bigner, D.D.; Rich, J.N. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res., 2006, 66(16), 7843-7848.
110. Cohen, M.H.; Shen, Y.L.; Keegan, P.; Pazdur, R. FDA drug approvalsummary: Bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist, 2009, 14(11), 1131-1138.
111. Fong, G.H. Mechanisms of adaptive angiogenesis to tissuehypoxia. Angiogenesis, 2008, 11(2), 121-140.
112. Menon, C.; Polin, G.M.; Prabakaran, I.; Hsi, A.; Cheung, C.; Culver, J.P.; Pingpank, J.F.; Sehgal, C.S.; Yodh, A.G.; Buerk, D.G.; Fraker, D.L. An integrated approach to measuring tumor oxygen status using human melanoma xenografts as a model. Cancer Res., 2003, 63(21), 7232-7240.
113. Rong, Y.; Durden, D.L.; Van Meir, E.G.; Brat, D.J. 'Pseudopalisading' necrosis in glioblastoma: A familiar morphologicfeature that links vascular pathology, hypoxia, and angiogenesis. J. Neuropathol. Exp. Neurol., 2006, 65(6), 529-539.
114. Venere, M.; Fine, H.A.; Dirks, P.B.; Rich, J.N. Cancer stem cells in gliomas: Identifying and understanding the apex cell in cancer'shierarchy. Glia, 2011, 59(8), 1148-1154.
115. Crocker, M.; Saadoun, S.; Jury, A.; Jones, C.; Zacharoulis, S.; Thomas, S.; Zwiggelaar, R.; Bridges, L.R.; Bell, B.A.; Papadopoulos, M.C. Glioblastoma blood flow measured with stable xenon CT indicates tumor necrosis, vascularity, and brain invasion. Neuro. Oncol., 2012, 14(5), 641-648.
116. Gu, Y.Z.; Moran, S.M.; Hogenesch, J.B.; Wartman, L.; Bradfield, C.A. Molecular characterization and chromosomal localization of athird alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr., 1998, 7(3), 205-213.
117. Huang, L.E.; Gu, J.; Schau, M.; Bunn, H.F. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependentdegradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA, 1998, 95(14), 7987-7992.
118. Kallio, P.J.; Wilson, W.J.; O'Brien, S.; Makino, Y.; Poellinger, L. Regulation of the hypoxia-inducible transcription factor 1alpha bythe ubiquitin-proteasome pathway. J. Biol. Chem., 1999, 274(10), 6519-6525.
119. Semenza, G.L. Targeting HIF-1 for cancer therapy. Nat. Rev.Cancer, 2003, 3 (10), 721-32.
120. Soeda, A.; Park, M.; Lee, D.; Mintz, A.; Androutsellis-Theotokis, A.; McKay, R.D.; Engh, J.; Iwama, T.; Kunisada, T.; Kassam, A.B.; Pollack, I.F.; Park, D.M. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1 alpha. Oncogene, 2009, 28(45), 3949-3959.
121. Bar, E.E.; Lin, A.; Mahairaki, V.; Matsui, W.; Eberhart, C.G. Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am. J. Pathol., 2010, 177(3), 1491-1502.
122. Bristow, R.G.; Hill, R.P. Hypoxia and metabolism. Hypoxia, DNArepair and genetic instability. Nat. Rev. Cancer, 2008, 8(3), 180-192.
123. Li, Z.; Bao, S.; Wu, Q.; Wang, H.; Eyler, C.; Sathornsumetee, S.; Shi, Q.; Cao, Y.; Lathia, J.; McLendon, R.E.; Hjelmeland, A.B.; Rich, J.N. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell, 2009, 15(6), 501-513.
124. Hirota, K.; Fukuda, R.; Takabuchi, S.; Kizaka-Kondoh, S.; Adachi, T.; Fukuda, K.; Semenza, G.L. Induction of hypoxia-inducible factor 1 activity by muscarinic acetylcholine receptor signaling. J. Biol. Chem., 2004, 279(40), 41521-41528.
125. Kaur, B.; Khwaja, F.W.; Severson, E.A.; Matheny, S.L.; Brat, D.J.; Van Meir, E.G. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro. Oncol., 2005, 7(2), 134-153.
126. Zundel, W.; Schindler, C.; Haas-Kogan, D.; Koong, A.; Kaper, F.; Chen, E.; Gottschalk, A.R.; Ryan, H.E.; Johnson, R.S.; Jefferson, A.B.; Stokoe, D.; Giaccia, A.J. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Develop., 2000, 14(4), 391-396.
127. Bar, E.E. Glioblastoma, cancer stem cells and hypoxia. BrainPathol., 2011, 21(2), 119-129.
128. Lathia, J.D.; Heddleston, J.M.; Venere, M.; Rich, J.N. Deadlyteamwork: Neural cancer stem cells and the tumor micro-environment. Cell Stem Cell, 2011, 8(5), 482-485.
129. Von Holst, A. Tenascin C in stem cell niches: redundant, permissiveor instructive? Cells Tissues Organs, 2008, 188(1-2), 170-177.
130. Sirko, S.; Akita, K.; Von Holst, A.; Faissner, A. Structural andfunctional analysis of chondroitin sulfate proteoglycans in the neural stem cell niche. Methods Enzymol., 2010, 479, 37-71.
131. Garcion, E.; Halilagic, A.; Faissner, A.; ffrench-Constant, C. Generation of an environmental niche for neural stem cell development by the extracellular matrix molecule tenascin C. Development, 2004, 131(14), 3423-3432.
132. He, J.; Liu, Y.; Xie, X.; Zhu, T.; Soules, M.; DiMeco, F.; Vescovi, A.L.; Fan, X.; Lubman, D.M. Identification of cell surface glycoprotein markers for glioblastoma-derived stem-like cells using a lectin microarray and LC-MS/MS approach. J. Proteome. Res., 2010, 9(5), 2565-2572.
133. Kawataki, T.; Yamane, T.; Naganuma, H.; Rousselle, P.; Anduren, I.; Tryggvason, K.; Patarroyo, M. Laminin isoforms and their integrin receptors in glioma cell migration and invasiveness: Evidence for a role of alpha5-laminin(s) and alpha3beta1 integrin. Exp. Cell Res., 2007, 313(18), 3819-3831.
134. Ljubimova, J.Y.; Fugita, M.; Khazenzon, N.M.; Das, A.; Pikul, B.B.; Newman, D.; Sekiguchi, K.; Sorokin, L.M.; Sasaki, T.; Black, K.L. Association between laminin-8 and glial tumor grade, recurrence, and patient survival. Cancer, 2004, 101(3), 604-612.
135. Vaupel, P.; Kallinowski, F.; Okunieff, P. Blood flow, oxygen andnutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res., 1989, 49(23), 6449-6465.
136. Chiche, J.; Brahimi-Horn, M.C.; Pouyssegur, J. Tumour hypoxia induces a metabolic shift causing acidosis: A common feature in cancer. J. Cell Mol. Med., 2010, 14(4), 771-794.